SAN DIEGO, June 16 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today a further expansion of its Research Grant program, adding $100,000 worth of reagents, cell culture tools and labware to support promising stem cell research.
"Even though the peak of the economic crisis appears to already have been reached, life scientists in the United States are still in desperate need for resources to keep their research projects alive," said Robert Balderas, Vice President of Biological Sciences, BD Biosciences. "BD Biosciences is proud to do its part to help advance some of the most promising stem cell and immunology research that could one day help cure or prevent disease."
When added to the existing $140,000 allocated to support immunology research, this new funding will bring the total annual support amount to $240,000, which will be distributed via 24 individual grants of BD Biosciences research reagents, cell culture tools and labware valued at $10,000 each.
The focus of the new stem cell research grants is to support the continuing study of embryonic, adult, and induced pluripotent stem cells to improve the understanding of both normal and disease processes. The program's immunology grants will support research in multicolor flow cytometry, cell signaling, cancer research, immune function, infectious diseases and neuroscience. Additional information about the grant program, including the application process and deadlines, is available at www.bdbiosciences.com/grant.
About the BD Biosciences Research Grant Program
BD Biosciences' Research Grant Program aims to reward and enable important research by providing vital funding for scientists pursuing innovative experiments to advance the scientific understanding of disease. The grant submissions are judged by a distinguished research panel of non-BD affiliated scientists. Through its grant program, BD Biosciences supports innovation in research and development that could lead to tomorrow's scientific breakthroughs.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD Biosciences